GlaxoSmithKline sets up $50 mln life sciences fund in Canada
Nov 10 (Reuters) - Pharmaceutical major GlaxoSmithKline is setting up a $50 million fund in Canada to invest in early stage research.
The GSK Canada Life Sciences Innovation fund will be managed by GSK in Canada and the company's venture capital division, SR One.
"The GSK Canada Life Sciences Innovation Fund will provide a competitive advantage to Canada's life sciences industry and help advance the commercialization of research," said Paul Lucas, chief executive of GSK.
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters